According to research report published this morning, Deutsche Bank has increased Medicis Pharmaceuticals' MRX PT from $41 to $44.
Deutsche Bank commented in the report, “On Tuesday, we hosted an in-depth meeting with Medicis management which included a detailed look at the company's key marketed products, development pipeline, business development activities, and growth outlook. Given our positive bias post this company visit, in tandem with positive momentum on the recent Zyclara launch, we continue to rate Medicis shares Buy.”
Medicis Pharmaceuticals closed yesterday at $38.23.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in